AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06433167 — intervention group
Intervention type: OTHER
Intervention: Pedobarographic analysis
Description: During the pedobarographic analysis, the patient takes steps on the platform at a regular walking speed, with arms relaxed at the sides, following a natural gait. In static analysis, measurements are taken while the patient remains stationary on the platform with arms in a relaxed position beside the body. Five measurements are separately recorded for both feet during the phases of stepping, heel strike, and toe lift. These measurements capture the highest pressures on the back of the foot, the middle part of the foot, and the inner, middle, and lateral sides of the front of the foot, including the toes. The pressure, force, and pressure-time integral corresponding to each area are then used to determine how and for how long these areas are exposed to pressure.
Study NCT05078593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Study NCT06522815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I plus
Description: CART-I PLUS collects signals in two ways:~ECG: Utilizes the metal on the inner and outer sides as electrodes to detect subtle electrical changes resulting from the contraction and relaxation of the heart muscle.~PPG: Emits LED light into the blood vessels inside the finger and collects the signal reflected by the blood flow, thereby gathering data on the pulse and functional oxygen saturation (SpO2) of arterial hemoglobin.~In this clinical trial, PPG signals will be continuously collected during the polysomnography using the PPG method.
Study NCT06522815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: In polysomnography, the following data are collected:~Electrocardiogram (ECG), Electroencephalogram (EEG), Electromyogram (EMG), Electrooculogram (EOG), Oxygen Saturation (SpO2) Respiratory Analysis, Body Position Monitoring
Study NCT06185231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussion Massage Group
Description: In addition progressive exercise program, The Percussion massage group will receive percussion massage therapy for a total of 5 minutes for each muscle group. The application will be done to the Quadriceps and Hamstring muscle groups before exercise. Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
Study NCT06185231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Group
Description: Conventional group undergo a progressive exercise program given as Phase-1, Phase-2, and Phase-3 for 6 weeks.~Neuromuscular Electrical Stimulation (NMES) will be applied to the Quadriceps muscle group for facilitation and reeducation purposes.
Study NCT05009953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: Irinotecan Liposome Injection, intravenously, over 90 min on days 1 of every 14-day cycle, 43mg/10mL
Study NCT05009953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, intravenously, over 60 min on days 1 of every 14-day cycle, 100mg/10mL
Study NCT05009953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on days 1 of every 14-day cycle
Study NCT05009953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (LV), intravenously, over 30 min on days 1 of every 14-day cycle
Study NCT04625699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 4 doses of Durvalumab 1500 mg IV Day 1, q28 days (For example, interventions involving drugs may include dosage form, dosage, frequency, and duration.)
Study NCT04625699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 2 doses of Tremelimumab 300 mg IV Day 1, q56 days
Study NCT05072028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]DBPR108
Description: \[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
Study NCT06270043 — intervention group
Intervention type: PROCEDURE
Intervention: Focal Therapy
Description: Focal ablation of prostate cancer using different modalities. These modalities include:~* Cryoablation or Cryotherapy~* Irreversible Electroporation - Nanoknife~* High Intensity Frequency Ultrasound - FocalOne~* Transurethral Ultrasound Ablation - TULSA - PRO
Study NCT04790578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZoeInsights Application
Description: ZI is designed to promote PA behavior change and maintenance via self-monitoring of PA, symptoms, and other health data. Additional information for using ZI will be provided via a PDF-based user guide on installing and using the application, a live instructional webinar hosted by ZI developer Hanalytics Solutions, and access to continued support via email/telephone communication with study staff as well as Hanalytics Solutions. Reminders to complete self-monitoring tasks will be provided using daily push notifications scheduled according to participant preferences. Automatic graphs will be generated and displayed within the app to allow participants to visualize trends in physical activity, symptoms, and other health data. ZI can be accessed via a web browser on any device that is connected to the internet (e.g. computer, laptop, tablet, smartphone), or via a native android or iOS mobile application on a smartphone or tablet.
Study NCT04790578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EXCEL Exercise Class
Description: The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
Study NCT04790578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXCEL Exercise Class
Description: The group based remote exercise program is delivered twice a week over the Zoom application. Classes are one hour long with a ten minute warm up, 40 minute strength and conditioning focused exercise circuits, and a ten minute stretching. Each class is followed by additional time to provide participants with an opportunity to interact with each other, fostering social support.
Study NCT06446414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choose to Move
Description: As described under study arm description
Study NCT05626309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhu Yuling Prescription
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Study NCT05626309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after esophageal cancer surgery.
Study NCT05132127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sutimlimab
Description: Pharmaceutical form: solution for injection Route of administration: intravenous (IV)
Study NCT05978206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone Decanoate
Description: Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
Study NCT05978206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy Intervention
Description: The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate.
Study NCT05978206 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy Intervention
Description: The physiotherapeutic intervention includes the following components:~1. Strength training will include strength exercises 3 x a week x 30 min - load from 60% to 80% 1RM for individual muscle groups, - 10 repetitions of the exercise, - 1-3 series in 1 session (break between sessions 60 seconds).~2. Endurance training will include aerobic exercises (cycle ergometer, treadmill, general fitness exercises) 3 times a week x 30 minutes, load from 60% to 80% of maximum heart rate.
Study NCT05978206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.
Study NCT05978206 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Intervention
Description: An individual diet in terms of calorific value and the content of energy substrates - proteins, fats and carbohydrates, as well as other nutrients, in accordance with specific nutrition standards.
Study NCT05978206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05183672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telecare consultation
Description: Using Zoom to communicate with patients
Study NCT05183672 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Usual face-to-face consultation
Description: Face-to-face communication with patients
Study NCT05060549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Participants will receive 6 weeks of cariprazine treatment
Study NCT05871320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [99mTc]Tc-TECANT1
Description: only one arm - the administration of \[99mTC\]-Tc-TECANT1 in all patients included
Study NCT05029908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Jaw Functional Limitation Scale
Description: DC/TMD Axis I TMD Pain Screener Questionnaire and TMD Symptom Questionnaire will be administered to the participants. To determine parafunctional habits and limitation of function, the DC/TMD Axis II assessment tools 'Jaw Functional Limitation Scale-8 (JFLS-8) and Oral Behavioral Checklist (OBC) will be applied. In addition, demographic data (age, gender, education level, occupation) will be questioned.
Study NCT04958876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-104
Description: oral capsule once daily
Study NCT04958876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone immediate release oral capsules
Description: oral capsule once daily
Study NCT05155670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WRL HX MCP
Description: WRL HX MCP is a non CE marked class IIa medical device designed for clinical application in hand rehabilitation; it consists in a cable-driven robotic MCP orthosis providing flexion-extension of the metacarpo-phalangeal joint. WRL HX MCP features and a series-elastic actuators (SEA) architecture for compliant actuation of MCP flexion-extension and a self-aligning mechanism to absorb human/robot joint axes misplacement. Exoskeleton module is mounted on a dorsal hand support and connected to its electronic box through wires.
Study NCT05596253 — intervention group
Intervention type: PROCEDURE
Intervention: TIPS
Description: TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
Study NCT05034159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Same as is described previously.
Study NCT06104553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1912; R-Chemo
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)
Study NCT06104553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1912; R-Chemo
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
Study NCT05456204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacological cardioversion with Refralon
Description: 1. the introduction of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight, diluted in 20 ml of saline intravenously for 2-3 minutes;~2. in the absence of effect (SR recovery did not occur), after 15 minutes,repeated intravenous administration of a 0.1% solution of refralon at a dose of 5 μg per 1 kg of body weight (total dose of the drug 10 μg / kg of body weight);~3. in the absence of effect (SR recovery did not occur),after 15 minutes, the next intravenous injection of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight (total dose of the drug 20 μg / kg of body weight);~4. in the absence of effect (recovery of SR did not occur), after 15 minutes, repeated intravenous administration of a 0.1% solution of refralon at a dose of 10 μg per 1 kg of body weight. Thus, the maximum total dose of the drug will be 30 μg/kg of body weight.
Study NCT06177288 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DEBIRI Combined With Chemotherapy and Bevacizumab
Description: After dissolving 100 mg of irinotecan in water for injection or 4ml of 5% glucose water.use 2mL of 70μm uniform particle size microspheres for loading and adsorption for 5minutes. Then mixed with non-plasma contrast agent to embolize the tumor feeding artery.
Study NCT06123702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear extinction
Description: Extinction of conditioned fear response
Study NCT06123702 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fear extinction
Description: Extinction of conditioned fear response
Study NCT06123702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Cap/Tab
Description: 12 50-mg capsules
Study NCT06123702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 placebo capsules
Study NCT05902949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Streching Group
Description: The Streching group will perform a conventional stretching exercise.
Study NCT06436989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hot purified water
Description: Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.
Study NCT06436989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hot purified water
Description: Hot purified water,drink once a workday,almost 360mL.Buy from regular channels.
Study NCT05200585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Liver/Hígado Sano program
Description: The program will last 4-6 months and include 16 sessions, each 30-60 minutes long, that focus on self-management strategies for dietary changes and physical activity and is meant to be delivered in 4-6 months. The 16 sessions are as follows: 1) Introduction to the program, 2) Get Active, 3) Track Your Activity, 4) Eat Well, 5) Track Your Food, 6) Get More Active, 7) Burn More Calories Than You Take In, 8) Shop and Cook, 9) Manage Stress, 10) Find Time for Fitness, 11) Cope with Triggers, 12) Keep Your Heart Healthy, 13) Take Charge of Your Thoughts, 14) Get Support, 15) Eat Well Away from Home, and 16) Staying Motivated
Study NCT05200585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual standard of care
Description: Participants will receive ongoing monitoring of condition at the clinic per standard of care and a short informational pamphlet
Study NCT05902949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heel group
Description: The heel pad group will be applied a plantar support during the months of the study.
Study NCT04917640 — intervention group
Intervention type: RADIATION
Intervention: Radiation Therapy
Description: Either SBRT or IMRT radiation therapy
Study NCT06310811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 Cells injection
Description: Patient will be treated with RD06-04 cells when enrolled in the study
Study NCT06310018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis
Description: Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis (treated with a total dose 8 mg tPA given as 2 mg/hour/catheter over 2 hours for first 10 patients followed by 50 patients treated with total dose 6 mg tPA given as 3 mg/hour/catheter given over 1 hour) with the EKOS+™ system
Study NCT03964389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: A lecture on neuroscience education (EN). The aim of this intervention is to provide participants with information in a clear and simple way so that patients can change their attitude to pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without tissue damage or with damage that justifies the perceived disproportion of pain.
Study NCT03361852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
Study NCT03361852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo Vax
Description: Neo Vax is an experimental viral mimic and an activator of immunity.
Study NCT03361852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a monoclonal antibody that targets PD-1. It is a type of immunotherapy
Study NCT06131606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: experimental group
Description: Patients in the experimental group were told how to use the stress ball before the procedure. The patient was then taken to the angiography unit. The stress ball was placed on the palms of the patients according to the procedure position. During the angiography, the researcher asked the patient to squeeze the stress ball once for every count of three. The angiography procedure lasted approximately 25-30 minutes. After the procedure, the NRS and STAI were filled out as a post-test 10 minutes after the patient was taken to the ward. The answers given by the patients were recorded by the researcher by marking them on the forms.
Study NCT06451133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MAP) goal of ≥65 mmHg
Description: The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.
Study NCT06451133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MAP) goal of 85-90 mmHg
Description: The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.
Study NCT06451133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg
Description: The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.
Study NCT06259578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
Description: 1 dose of 0.5 ml containing inactivated SARS-CoV-2 virus (5 μg ), Tween 80, histidine, Polysorbate 80, Aluminium hydroxide gel, and sodium chloride
Study NCT04920942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.4mg/kg/day for 5 days
Description: Ivermectin 0.4mg/kg/day for 5 days with standard-of-care
Study NCT04768855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered IV or SC.
Study NCT04768855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV or SC.
Study NCT04768855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3540378
Description: Administered SC.
Study NCT04818008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program
Description: A Home-based Exercise Program to improve strength and balance and prevent falls.
Study NCT05499273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scalpel-bougie tracheostomy
Description: 1. The assistant places themselves with two preparation clamps at the head end of the table and assists with each hand placed lateral to the neck, so that the operating field is freely accessible. After the trachea or cricoid is palpated, a long median longitudinal skin incision of 2-3 cm is made from the cricoid caudally~2. The assistant uses straight clamps to pull the two edges of the skin incision apart dorso-laterally. In the event of major bleeding this maneuver should allow the blood to drain off dorsally and the view of the anatomical structures should be less impaired.~3. Layer by layer of the anatomical structures are cut through with the scalpel and tightened with the clamps accordingly.~4. Using a longitudinal incision, two to three tracheal rings are cut through distally to the cricoid~5. An 8 FR Frova catheter is inserted through the orifice into trachea.~6. A tracheal tube (ID 3.0 mm) is inserted over the Frova catheter to secure the airway permanently.